glucokinase activator + placebo

This entry refers to the combination of a glucokinase activator (GKA) and a placebo, as typically used in randomized controlled clinical trials for diabetes. Glucokinase activators are small molecule drugs that enhance the activity of glucokinase (GCK), an enzyme critical for glucose sensing and metabolism in pancreatic β-cells and hepatocytes. By increasing GCK activity, these agents aim to improve insulin secretion and hepatic glucose uptake, thereby lowering blood glucose levels. Placebo is an inert substance used as a control in clinical studies. GKAs have been investigated primarily for type 2 diabetes mellitus; some newer agents are also being studied as adjuncts in type 1 diabetes. Notable GKAs include dorzagliatin, TTP399 (cadisegliatin), PB-201 (PF04937319), among others[6][8][9][10]. The mechanism of action involves allosteric activation of glucokinase, leading to increased phosphorylation of glucose to glucose-6-phosphate[1][3]. Clinical trials compare the efficacy and safety profile of GKA versus placebo.

Other names

GCK activator + placeboGK activator + placebo